Dementia Market Size 2024: Epidemiology, Industry Trends and Forecast by 2034

Previous Topic Next Topic
 
classic Classic list List threaded Threaded
1 message Options
Reply | Threaded
Open this post in threaded view
|

Dementia Market Size 2024: Epidemiology, Industry Trends and Forecast by 2034

HealthcareMarket29
Dementia Market Overview:

Report Attribute
        Details
Base Year  2023
Forecast Years  2024-2034
Historical Years 
2018-2023


Market Size in 2023
        US$ 6.8 Billion

Market Forecast in 2034
        US$ 12.8 Billion

Market Growth Rate 2024-2034
        5.85%

What is the dementia market value?

The dementia market reached a value of US$ 6.8 Billion in 2023 and expected to reach US$ 12.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.85% during 2024-2034.

The report offers a comprehensive analysis of the dementia market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the dementia market.

Request for a Sample Copy of this Report: https://www.imarcgroup.com/dementia-market/requestsample

Dementia Market Trends:

Dementia is a progressive syndrome that affects cognitive function, particularly memory, thinking, and reasoning. The dementia market is poised for substantial growth due to several key drivers. Firstly, the rising geriatric population contributes significantly to the market's expansion. As people age, the risk of developing dementia increases, thereby amplifying the demand for treatments and therapies. Additionally, elevated awareness and diagnosis rates are pivotal factors propelling market growth. Improved understanding of dementia symptoms among both healthcare professionals and the general public leads to earlier detection and intervention. This, in turn, fuels the need for medications and supportive care, stimulating the market's progression. Moreover, ongoing advancements in medical research and technology play a crucial role in driving the dementia market forward. Continuous efforts in developing innovative therapies, including precision medicine and gene therapy, hold promising potential for effective treatments, enticing investment, and fostering market growth.

Furthermore, the expanding healthcare expenditure contributes to the market's buoyancy. Governments and private sectors increasingly allocate funds to address the growing healthcare burden of dementia, facilitating research, development, and accessibility to treatments. The elevating prevalence of risk factors associated with lifestyle choices, such as obesity, diabetes, and cardiovascular diseases, also influences the dementia market. Addressing these risk factors becomes a priority, fostering preventive measures and interventions, thereby impacting the market landscape. Lastly, collaborations and strategic alliances between pharmaceutical companies, research institutions, and advocacy groups accelerate market growth.

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the dementia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the dementia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current dementia marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape  :

The competitive landscape of the dementia market has been studied in the report with the detailed profiles of the key players operating in the market.

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=7419&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163